目的 研究蓯蓉益腎顆粒聯(lián)合鹽酸普拉克索片治療帕金森病的臨床療效。方法 選取2016年5月-2019年5月在天津市東麗區(qū)東麗醫(yī)院治療的100例帕金森病患者為研究對象，將所有患者隨機分為對照組和治療組，每組各50例。對照組患者口服鹽酸普拉克索片，第1周起始劑量為0.375 mg/d，第2周0.75 mg/d，每周加量1次，每次日劑量增加0.75 mg，每日最大劑量為4.5 mg，3次/d；治療組在對照組治療的基礎上口服蓯蓉益腎顆粒，1袋/次，2次/d。兩組患者持續(xù)治療3個月。觀察兩組的臨床療效，比較兩組的簡易智力狀態(tài)檢查量表（MMSE）評分、統(tǒng)一帕金森病評分量表（UPDRS）評分、血清胱抑素C（Cys-C）和丙二醛（MDA）水平。結(jié)果 治療后，對照組和治療組的總有效率分別為74.00%、94.00%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者MMSE評分顯著升高，UPDRS評分顯著降低，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組MMSE評分和UPDRS評分均明顯優(yōu)于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者血清Cys-C和MDA水平均顯著降低，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組血清Cys-C和MDA水平均明顯低于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。結(jié)論 蓯蓉益腎顆粒聯(lián)合鹽酸普拉克索片治療帕金森病具有較好的療效，可改善患者MMSE評分和UPDRS評分，降低血清Cys-C和MDA水平，具有一定的臨床推廣應用價值。

Objective To study the effect of Congrong Yishen Granules combined with Pramipexole Dihydrochloride Tablets in treatment of Parkinson's disease. Methods Patients (100 cases) with Parkinson's disease in Tianjin Dongli Hospital from May 2016 to May 2019 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Pramipexole Dihydrochloride Tablets, the initial dose was 0.375 mg/d in the first week, the dose was increased to 0.75 mg/d in the second week, after that, the dose increased 1 times a week, increased 0.75 mg every time, and the maximum daily dose was 4.5 mg, three times daily. Patients in the treatment group were po administered with Congrong Yishen Granules on the basis of the control group, 1 bag/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and MMSE score, UPDRS score, the levels of Cys-C and MDA in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.00% and 94.00%, respectively, and there was difference between two groups (P<0.05). After treatment, the MMSE score in two groups were significantly increased, but the UPDRS score in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of Cys-C and MDA in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the levels of Cys-C and MDA in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Congrong Yishen Granules combined with Pramipexole Dihydrochloride Tablets has clinical curative effect in treatment of Parkinson's disease, can improve MMSE score and UPDRS score, and reduce the levels of Cys-C and MDA, which has a certain clinical application value.

R971